Description
DECREASE FUNDING REQUIRED. IGF OT IGF RADIUM-223 DICHLORIDE (XOFIGO)
Base award description: IGF::OT::IGF RADIUM-223 DICHLORIDE (XOFIGO)
Modification chain · 3 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2018-10-01+$209,932= $209,932
- Mod P000012019-09-11+$99,941= $309,873
- Mod P000022020-04-03-$87,035= $222,838
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2018-10-01 | +$209,932 | $209,932 | IGF::OT::IGF RADIUM-223 DICHLORIDE (XOFIGO) |
| Mod P00001· FUNDING ONLY ACTION | 2019-09-11 | +$99,941 | $309,873 | ADDITIONAL FUNDING REQUIRED. IGF OT IGF RADIUM-223 DICHLORIDE (XOFIGO) |
| Mod P00002· FUNDING ONLY ACTION | 2020-04-03 | −$87,035 | $222,838 | DECREASE FUNDING REQUIRED. IGF OT IGF RADIUM-223 DICHLORIDE (XOFIGO) |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI V1EVGCK7XES8)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C25626N0492 | 256-NETWORK CONTRACT OFFICE 16 (36C256) · 6505 · DRUGS AND BIOLOGICALS | $386,860 | FY2026 |
| 36C26226F0163 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS | $181,386 | FY2026 |
| 36C26026F0086 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $80,663 | FY2026 |
| 36C26126N0199 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $101,567 | FY2026 |
| 36C25626N0126 | 256-NETWORK CONTRACT OFFICE 16 (36C256) · 6505 · DRUGS AND BIOLOGICALS | $214,783 | FY2026 |
| 36E79725A0028 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2025 |
Other recipients under 6505 from 250-NETWORK CONTRACT OFFICE 10 (36C250) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C25026P0991 | ASD SPECIALTY HEALTHCARE, LLC | 250-NETWORK CONTRACT OFFICE 10 (36C250) | $43,680 | FY2026 |
| 36C25026F0668 | COSETTE PHARMACEUTICALS, INC. | 250-NETWORK CONTRACT OFFICE 10 (36C250) | $10,398 | FY2026 |
| 36C25026N0655 | PROGENICS PHARMACEUTICALS INC | 250-NETWORK CONTRACT OFFICE 10 (36C250) | $721,744 | FY2026 |
| 36C25026N0616 | AMERICAN NATIONAL RED CROSS, THE | 250-NETWORK CONTRACT OFFICE 10 (36C250) | $37,180 | FY2026 |
| 36C25026D0061 | AMERICAN NATIONAL RED CROSS, THE | 250-NETWORK CONTRACT OFFICE 10 (36C250) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C25019F0071_3600_VA25114A0051_3600 · retrieved 2026-09-26.